← Back to Clinical Trials
Recruiting Phase 4 NCT06523465
Statin Combined with Amlodipine Treats Primary Aldosteronism
Trial Parameters
Condition Primary Aldosteronism
Sponsor Third Military Medical University
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 180
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2024-09-10
Completion 2025-12-30
Interventions
Simvastatin combined with Amlodipine besylateSimvastatin combined with Spironolactone and Amlodipine besylate.Amlodipine besylate combined Spironolactone
Brief Summary
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness